Navigation Links
Positive Results from Phase IIa Study Pave Way for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes
Date:6/14/2011

TAIPEI, Taiwan, June 14, 2011 /PRNewswire-Asia/ -- TWi Biotechnology Inc. announced today that the company has enrolled over 50% of the total 240 patients for the Phase IIb clinical trial of AC-201 for the treatment of Type II Diabetes. The randomized, double-blind, placebo-controlled, dose-ranging, multi-center study is primarily designed to evaluate the glycated hemoglglobin A1c (HbA1c) lowering effects of AC-201 in patients with Type II Diabetes Mellitus. Meanwhile, the cardiovascular safety profile will be carefully monitored according to U.S. FDA's guidance. In addition to primary objective, by measuring various biomarkers, the company is able to stratify different patient groups in terms of clinical response, so as to develop personalized, preventive or therapeutic strategies.

"The initiation of Phase IIb study is a major milestone for TWi Biotechnology as we continue to demonstrate the potential efficacy of AC-201," stated Dr. M. Sherry Ku, President & CSO of TWi Biotech. "During the previous Phase IIa study, those patients with inadequate blood glucose control by up to three drug combinations of currently available oral anti-diabetic drugs were treated with AC-201 as an add-on therapy. The Phase IIa proof-of-concept study showed a mean reduction of 0.63% for HbA1c (N=56, p<0.05) at the end of 24 weeks treatment period, which is very promising and encouraging. The detailed results of the Phase IIa study will be presented in the American Diabetes Association (ADA) 71st Annual Meeting Scientific Sessions (June 24-28, 2011) in San Diego, California, USA. With the positive Phase IIa results, we are confident to begin enrolling patients for Phase IIb study in March 2011. As of today, we have enrolled more than 50% of the total 240 patients in U.S. and Taiwan. We are expecting to complete patient enrollment by the end of this year. Our plan is to develop AC-201 as an add-on therapy and/or as a mono therapy for Type II Diabetes."

<
'/>"/>

SOURCE TWi Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
2. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
3. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
4. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
5. Positive SPA Reply From the FDA for TopoTargets Pivotal Trial With Belinostat in PTCL
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
8. InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results
9. Kuvan Receives Positive Opinion From CHMP for European Approval
10. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
11. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... February 27, 2015 Immunovaccine Inc. ... immunotherapy company, today announced that the U.S. Food ... Fast Track designation and Phase I clinical trials ... with the mutual co-development agreement signed with Gilead ... Track designation for the DPX-Survivac. , “We have ...
(Date:2/27/2015)... 2015 FamilyFarms Group is pleased to ... State Line Farms, received the 2015 Tomorrow’s Top Producer ... the age of 35, who has demonstrated excellence in ... to win the Tomorrow's Top Producer Horizon Award. Every ... Top Producer Award and learning from their experiences. It ...
(Date:2/26/2015)... 26, 2015 S&P Capital IQ (MHFI) announced ... coverage on MabVax Therapeutics Holdings Inc . ... stage biotechnology company focused on the development of vaccine ... the treatment of cancer. MabVax has discovered a pipeline ... immune responses generated by patients who have been immunized ...
(Date:2/26/2015)... --  Synageva BioPharma Corp. (NASDAQ: ... for rare disorders, today reported 2014 full year ... objectives, and financial guidance.  Synageva,s management team will ... EST to review the financial results and provide ... call by telephone, please dial (877) 445-4603 for ...
Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... to air a sitcom set in mythical Waterford Falls, Wis., ... limelight whether it wants to or not. , ,Consider ... Macdonald of Saturday Night Live and Norm fame, may not ... the show makes it sound like a neurotic Green Acres, ...
... MADISON, WI - Even as the State Assembly Ways and ... -- a measure that would end state and local sales ... was passing a measure that, if it becomes law, would ... passed H.R. 49 , which would permanently extend an ...
... proposal? Legislative Republicans voted for it because they thought it ... freeze was good policy and secretly hoped Doyle would veto ... Gov. Jim Doyles proposal to raise the state minimum wage, ... such a populist bill if it reaches the floor of ...
Cached Biology Technology:Maybe its time to write our own television shows about Wisconsin 2State and Feds Race to Stop Taxation of Internet Access 2State and Feds Race to Stop Taxation of Internet Access 3State and Feds Race to Stop Taxation of Internet Access 4Doyle and the Legislature Have Much To Agree Upon When It Comes To The Economy 2Doyle and the Legislature Have Much To Agree Upon When It Comes To The Economy 3
(Date:2/5/2015)... 26, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... http://www.nxt-id.com/ ) as part of its 2015 marketing and ... launched its new consumer website for Wocketwallet.com earlier this ... of NXT-ID said, "Our new corporate website naturally showcases ...
(Date:2/5/2015)... Jan. 28, 2015 Research and Markets ... of the "Global Biometrics Market (2014-2020): Market ... Countries " report to their offering. , ... Asia-Pacific is anticipated to overtake ... to increasing government spending towards IT security, government ...
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ... in general the State of Washington,s ... a new enrollment and central issuance system for driver,s licenses ... The project planning and development will start in January ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Valid USA Signs Contract For Washington Driver's License Issuance 2
... local waste partnerships towards the achievement of central targets ... objectives, a study funded by the Economic and Social ... disposing of it in environmentally acceptable ways are significant ... public service delivery, partnership working is a now a ...
... tinker with a single amino acid of an enzyme ... to molecular biologists who say the discovery could pave ... making vaccines. "We have successfully tested this technique with ... biochemistry and molecular biology at Penn State. "And we ...
... quench their thirst according to new research by a ... species, including certain types of beetles, moths and crickets, ... account for around 10% of their body weight. The ... simply to get hold of the water in the ...
Cached Biology News:Central targets may hinder wider waste management objectives 2Central targets may hinder wider waste management objectives 3Discovery may help defang viruses 2Discovery may help defang viruses 3Sex is thirst-quenching for female beetles 2
... Sampler Kit Kit Includes: Histone ... ul Histone Deacetylase 3 (HDAC3) Antibody, Catalog ... Antibody, Catalog #2072, 40 ul Histone Deacetylase ... Histone Deacetylase 6 (HDAC6) Antibody, Catalog #2162, ...
Immunogen: Synthetic Peptide: C N(185) D G T E F G G S I Y Q K(197) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Use the DUALmembrane kit 3 to carry out DUALmembrane interaction analysis and cDNA library screening to characterize interactions between integral membrane proteins and to identify novel interaction ...
PlusOne EDTA, disodium salt, 100 g. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Buffers....
Biology Products: